This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ABRAXANE® Extends Survival By Nearly Two Months For Patients With Advanced Pancreatic Cancer





MANHATTAN BEACH, Calif., Jan. 22, 2013 /PRNewswire/ -- The Pancreatic Cancer Action Network is pleased to announce that today Celgene Corporation (Celgene) reported that the combination of its chemotherapeutic drug ABRAXANE® with gemcitabine improved overall survival in patients with metastatic pancreatic cancer by nearly two months (8.5 months vs. 6.7 months) when compared with gemcitabine alone. According to Celgene, this combination also demonstrated a 59 percent increase in one-year survival compared to patients receiving gemcitabine alone.

(Logo: http://photos.prnewswire.com/prnh/20111004/LA79914LOGO)

"The positive results of this trial indicate another step forward in the treatment of this insidious disease where historically few effective treatment options have existed.  This success also illustrates that clinical trials can give pancreatic cancer patients access to state-of-the art treatments that may be their best option.  We are pleased that patients will have another choice when making treatment decisions," stated Julie Fleshman, president and CEO of the Pancreatic Cancer Action Network.  "Further, this positive news brings us one step closer to doubling the survival rate of pancreatic cancer by 2020."

The phase III study included 861 metastatic pancreatic cancer patients from around the world.  Celgene plans to submit their findings to the FDA for approval of ABRAXANE in pancreatic cancer.  ABRAXANE was previously approved for breast cancer in 2005 and in October 2012 was approved for a type of lung cancer. It is a form of the chemotherapy drug paclitaxel that is modified by the addition of a human protein called albumin.

The Pancreatic Cancer Action Network encourages all patients to consider clinical trials when exploring treatment options. The organization has a comprehensive up-to-date database of all approved pancreatic cancer-specific clinical trials taking place nationwide and can do a customized eligibility search for patients through our Patient and Liaison Services program.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,095.22 +83.28 0.46%
S&P 500 2,113.23 +3.63 0.17%
NASDAQ 5,097.6340 +21.11 0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs